Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Understanding the Macular Degeneration Chart: Types, Stages, Symptoms, and Next Steps

Posted by: Northwest Eye in macular degeneration chart on April 9, 2026

Start with what the chart represents

A macular degeneration chart organizes general eye findings, stages, symptoms, or monitoring steps. It does not tell you what is happening in your eyes by itself.

Age-related macular degeneration, usually shortened to AMD, can blur or damage your central vision. AMD affects the macula, the part of your retina that helps you see fine detail, and it usually does not cause pain. The macula provides sharp central vision, so damage there can make the center of your view look blurry, distorted, or dark.

A chart may show labels such as dry AMD, wet AMD, early, intermediate, late, drusen, pigment changes, or geographic atrophy. These labels describe patterns that clinicians look for; they do not establish your diagnosis or predict your personal timetable.

Use a chart or an Amsler grid as general information or monitoring, not as a diagnosis. An eye examination and, when needed, retinal imaging are needed to determine what is causing a change.
An estimated 11 million Americans have some form of AMD. That estimate describes the condition in the United States, not your personal likelihood of having it.

An Amsler grid is also limited as a diagnostic test. In one systematic review, reported sensitivity and specificity varied depending on the comparison group. Sensitivity measured how often the test identified eyes with the condition, while specificity measured how often it correctly classified eyes without it in that study group.

When the comparison group had no retinal pathology, the same review reported 67% sensitivity and 99% specificity. Different comparison groups produced different results, so neither set of percentages can be used as your personal result.

Identify whether the chart says dry or wet

AMD is commonly described as dry or wet based on physical changes affecting the retina and macula. Dry AMD is more common. Wet AMD is less common but can cause faster and more severe vision loss.

About 80 percent, or 8 out of 10, people who have AMD have the dry form. This is a proportion of people with AMD, not a prediction about which form you have.

Dry AMD can involve thinning of the macula, yellow deposits called drusen, pigment changes, or geographic atrophy. Geographic atrophy means an area of retinal cell loss, and it can cause central-vision loss. Wet AMD happens when abnormal new blood vessels grow under the retina and leak blood or fluid. The leakage can scar and damage the macula.

The causes of AMD are not fully understood. AMD has multiple contributing factors.

Risk factors linked with AMD include:

  • Smoking.
  • Excess weight, including weight around the abdomen.
  • Unchecked cardiovascular disease or high blood pressure.
  • Long-term sun exposure without eye protection.

AMD is common among people over age 50 and is described as the leading cause of central vision loss in the United States. If you smoke, quitting is the prevention method known to reduce the risk of developing AMD. That action changes risk; it does not replace an eye evaluation.

Some people with dry AMD may use a home-monitoring device when it is appropriate for their condition. The ForeseeHome Monitor is an FDA-cleared device for some patients with dry AMD, is designed for daily use, and takes approximately 3 minutes per eye.

A home device is not the same as a diagnosis from a chart. Whether it belongs in your monitoring plan depends on your eye findings and the recommendations of your eye-care professional.

An infographic about AMD forms shows that 80% of people with AMD have the dry form and that ForeseeHome use takes approximately 3 minutes per eye. The figures describe population share and device-use time.
Dry AMD is more common, while home monitoring applies only to some patients.

Read the early, intermediate, and late labels

Clinical AMD staging uses three stages—early, intermediate, and late—based on findings such as drusen size and pigment changes within 2 disc diameters of the fovea in people older than 55. A chart may therefore describe what was seen during an eye examination rather than what you feel day to day.

Drusen are yellow deposits beneath the retina that a physician can see during a dilated eye examination. Some very small drusen are a normal part of aging, while medium-to-large drusen may indicate AMD. Pigment changes beneath the retina can appear as dark clumps or as areas with less pigment.

This simplified table shows how common chart labels are generally used:

Chart label Findings that may appear on the chart Usual vision pattern
Early AMD Medium-sized drusen. One clinical classification defines these as larger than 63 µm and no more than 125 µm, without pigmentary abnormalities. Little or no noticeable effect on vision is typical.
Intermediate AMD Larger or more numerous drusen, large drusen greater than 125 µm, pigment changes, or both. Some people notice mild central blurring or trouble seeing in low light. Others have no symptoms.
Late AMD Neovascular AMD, geographic atrophy, or both. Central-vision loss is present. The late form may be dry or wet.

The measurements in this classification describe retinal findings assessed within 2 disc diameters of the fovea for the stated population. They are not measurements you can make reliably from a printed chart or home screen.

A clinical trial involving over 1500 participants reported that 87% to 94% of ForeseeHome users maintained 20/40 vision or better when wet AMD was detected, compared with 62% of people using conventional methods such as the Amsler grid. Those percentages describe the trial groups and the vision level measured at wet AMD detection. They do not predict what will happen to your vision or show that the device is suitable for you.

Match the chart with changes in central vision

AMD symptoms can include blurry central vision, wavy or crooked straight lines, a blank or dark spot, less-bright colors, and trouble seeing in dim light. The specific pattern depends on the type and stage of disease.

Early AMD often causes little or no noticeable change. Intermediate AMD may cause mild central blur or difficulty seeing in low light, although some people still have no symptoms. Late AMD causes central-vision loss and may make a blurry area or blank spot near the center of your view more noticeable.

Symptoms can appear in one eye, both eyes, or neither eye at first. A lack of symptoms does not establish that the retina is normal, because comprehensive exams can find AMD before you notice vision changes.

Macular degeneration can affect tasks that depend on central detail, including reading, writing, driving, and recognizing faces. Dry macular degeneration usually causes a gradual change, although it can eventually affect central vision and cause blurring.

Wet AMD behaves differently. Abnormal blood vessels under the retina can leak or burst, causing distortion, blank spots, and rapid vision decline. Some people develop severe visual impairment within days or weeks of wet AMD onset. A chart that shows dry AMD does not tell you that wet AMD will develop, and a chart that shows a stage does not tell you how quickly your vision will change.

Treat the chart as a snapshot, not a timetable

AMD progression depends on the type of AMD and your personal risk factors. Dry AMD often progresses slowly over the years, while wet AMD can progress rapidly over days or weeks and requires urgent care.

AMD staging can help estimate the risk of progressing to advanced disease, including geographic atrophy and neovascularization. It does not provide a fixed schedule. The location and growth pattern of a lesion can affect visual impairment and quality-of-life effects, and these outcomes vary greatly between people.

That variation is why a chart should be read as a snapshot of findings at a particular point in care. It can help you understand a conversation with an eye doctor, but it cannot tell you the date of a future change.

Geographic atrophy growth has varied significantly between people in published research. One review reported enlargement rates from 0.53 to 2.6 mm² per year, with a median of 1.78 mm² per year. These figures measure lesion-area enlargement in the reviewed research; they are not a forecast for your eye.

In a separate sample of 212 eyes from 131 patients with AMD, mean enlargement was 0.8 mm² per year for lesions initially sized at 1.3 mm², 2.1 mm² per year for lesions between 1.3 and 8.3 mm², and 3.0 mm² per year for lesions larger than 8.3 mm². The results came from that study sample and do not establish an individual rate.

The same research also describes a possible level-off effect: once a lesion is greater than 10DA, the link between lesion size and enlargement rate may become less pronounced. This technical finding does not make a larger lesion predictable from its size alone.

When you compare a chart with an older chart, look for the date, the eye examined, the type of imaging used, and the wording of the findings. Ask what changed and what remained stable. Do not convert a research rate into a personal timetable.

Confirm the labels with an eye evaluation

An AMD evaluation combines your symptoms and health history with a comprehensive eye examination. Regular comprehensive, dilated eye exams can find AMD before you notice vision changes. Drops widen your pupils so the specialist can examine the retina and look for AMD or other eye problems.

Your clinician may ask about:

  • Changes such as distortion, decreased vision, blind spots, light flashes, or difficulty adjusting to darkness.
  • Medicines and nutritional supplements.
  • Your eye history and general health.
  • Family history of AMD.
  • Smoking.

The clinician also examines the macula directly. This helps connect the chart label with what is actually present in your eye.

Optical coherence tomography, or OCT, is a scan that creates detailed images of the retina and macula. It can show fluid that an examination alone may not reveal and can track structural changes. Those details are especially useful when a clinician is evaluating possible wet AMD or following changes over time.

Fluorescein angiography may also be used to examine retinal blood vessels. Dye is injected into a vein, usually in your arm, and a special camera photographs the retina as the dye moves through its vessels. Your clinician decides whether that test is needed.

A 2014 ophthalmology passage described OCT as standard of care for treating diabetic macular edema or wet AMD. That statement describes the treatment context named in the passage; it does not mean every chart finding requires the same test.

Use an Amsler grid as a monitoring tool

An Amsler grid is a square grid with a dot in the middle. When used correctly once a day, it can show problem spots in your field of vision. The grid checks whether lines look wavy or distorted or whether areas of your visual field are missing.

Use the grid in the same way each time:

  1. Keep it at eye level in consistent light without glare.
  2. Put on your usual reading glasses.
  3. Hold it 12 to 15 inches from your face.
  4. Cover one eye without pressing on it.
  5. Look directly at the center dot and keep your gaze there.
  6. Notice whether any lines or areas look blurry, wavy, dark, blank, distorted, or missing.
  7. Repeat the check with the other eye.

Test each eye separately and keep the grid the same distance from your eyes each time.

An Amsler grid can help you notice a change, but it cannot reliably detect every transition to neovascular AMD. In one systematic review, the grid had 71% sensitivity for detecting neovascular AMD when tested against patients with nonneovascular AMD. The review also found that the grid correctly classified only 63% of people who had transitioned from dry to neovascular AMD.

The same review found sensitivity at levels typically not recommended for monitoring. These results describe the test in study groups, not your personal risk. A normal-looking grid does not rule out AMD or another retinal problem, and an unusual grid does not identify its cause.

If a grid line looks newly wavy, dark, blurry, blank, or more distorted than before, arrange to see an eye doctor at once. Contact an ophthalmologist right away for a new or worsening change. Bring the grid or a marked copy if that helps you describe what you saw, but do not wait for repeated home checks to confirm a new change.

Connect the chart category with general management

AMD management depends on the type, stage, retinal findings, symptoms, and the condition of each eye. A chart can show why different people receive different plans even when their labels sound similar.

For early AMD, regular comprehensive dilated exams may be recommended to check whether the condition is advancing. For patients with no clinical signs of AMD, identified as AREDS category 1, the recommendations list observation with no medical or surgical therapies.

The recommendations also list antioxidant vitamin and mineral supplements as recommended in the original AREDS and AREDS2 reports. That wording does not mean every supplement is appropriate for you. Do not start a supplement based only on a chart; discuss the specific formulation and your health history with a qualified professional.

Wet AMD is commonly treated with anti-VEGF injections. These medicines help stop bleeding and leakage from abnormal blood vessels and are used to slow vision loss from wet AMD. The recommendations list aflibercept, bevacizumab, and ranibizumab among intravitreal injections for eligible AMD diagnoses.

Anti-VEGF injections usually work for only a short time. Most people initially need injections once a month and later follow the schedule their doctor recommends. The schedule depends on your examination and response, so a chart cannot determine how many injections you need.

Geographic atrophy has different management considerations. Pegcetacoplan and avacincaptad pegol have been shown to slow its development by up to 20%. That figure measures slowing of geographic-atrophy development; these medicines do not improve vision or prevent vision loss.

In 2024, the U.S. Food and Drug Administration authorized the Valeda Light Delivery System through the de novo pathway for multiwavelength photobiomodulation treatment of patients with non-neovascular AMD. This authorization describes a specific device and patient condition. It does not mean the device is suitable for every dry AMD finding.

Treatment guidance can change as new evidence and authorizations emerge. Use the chart to prepare questions, then let an eye evaluation connect the label with an appropriate plan.

A checklist infographic about AMD management lists observation and regular exams for early AMD, treatments that can slow geographic atrophy development by up to 20%, and anti-VEGF injections commonly used for wet AMD.
The chart category helps frame questions, but an eye evaluation determines the plan.

Arrange prompt help for warning signs

New or worsening distortion needs prompt eye care. Arrange to see your eye doctor at once if straight lines become newly wavy or if an area looks darker, wavy, blank, or blurry.

Prompt evaluation and treatment matter when neovascular AMD is active. Symptoms suggesting infection after an eye injection or retinal detachment require prompt evaluation. Do not wait for a scheduled monitoring check when a new change appears.

An estimated 80% of patients with AMD have non-neovascular or atrophic AMD, while neovascular AMD is responsible for most of the severe vision loss associated with AMD. This population estimate explains why a new change still needs assessment even if an earlier chart showed a dry or non-neovascular category.

Sudden vision loss is a medical emergency. Seek qualified eye or medical help as soon as possible because sudden loss may signal retinal detachment, stroke, or another serious condition.

Wet AMD usually progresses quickly, and vision loss can occur within days if it is untreated. That timing describes the potential course of untreated wet AMD; it is not a reason to diagnose yourself from a chart. If your vision suddenly changes, seek urgent help rather than trying to match the symptom to a stage diagram.

Book an eye appointment to review the chart

A macular degeneration chart can help you name a finding, but an eye examination is needed to determine what the finding means for your eyes. Bring the chart, its date, and a list of any new changes, including which eye is affected and when you first noticed them. A qualified professional can decide which examination or retinal imaging is appropriate.

If you have new distortion, dark or blank areas, or sudden vision loss, use the warning guidance above rather than waiting for a routine review. For an eye evaluation and a clear explanation of your chart, contact Northwest Eye in Minnetonka.

What should I do if my chart or Amsler grid looks different?

Can a macular degeneration chart predict how quickly my vision will change?

No. A chart shows findings at a particular point in care, but it cannot provide your personal timetable. Progression depends on the AMD type, retinal findings, lesion location, and individual risk factors. Dry AMD often changes slowly, while wet AMD can worsen rapidly. Your eye doctor must compare examinations and imaging over time.

What does it mean if a chart mentions drusen?

Drusen are yellow deposits beneath the retina that a doctor can see during a dilated eye examination. Some very small drusen are a normal part of aging, while medium-to-large drusen may indicate AMD. Their presence alone does not establish your diagnosis or stage, so the finding should be interpreted with other examination results.

What should I bring when I ask an eye doctor about a chart?

Bring the chart, its date, and a list of vision changes. Note which eye is affected and when you first noticed the change. Include your medicines, supplements, eye history, general health conditions, family history, and smoking history. This information helps the clinician connect the chart with an examination and decide whether retinal imaging is needed.

When is a vision change an emergency rather than a routine chart question?

Sudden vision loss is a medical emergency, so seek qualified eye or medical help as soon as possible. New or worsening distortion, or a dark, wavy, blank, or blurry area, requires prompt eye care. Do not wait for repeated home checks or a scheduled visit, especially after an injection if symptoms suggest infection or retinal detachment.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information